# Relay Therapeutics appoints Bicara CEO to board ahead of breast cancer trial

Relay Therapeutics (RLAY) has appointed Bicara Therapeutics' (BCAX) CEO, Claire Mazumdar, to its Board of Directors as it prepares to initiate its Phase 3 ReDiscover-2 trial in breast cancer; Mazumdar's background includes business development at Rheos Medicines and company formation at Third Rock Ventures. Separately, Bicara Therapeutics has received positive analyst updates from Stifel and Cantor Fitzgerald following promising clinical data regarding its ficerafusp treatment, though analysts urge caution in drawing definitive conclusions due to the nature of the patient cohorts.

Analysis

Relay Therapeutics (NASDAQ:RLAY) has enhanced its Board of Directors by appointing Dr. Claire Mazumdar, CEO of Bicara Therapeutics (NASDAQ:BCAX), a strategic addition that brings significant clinical-stage oncology, operational, and business development experience as Relay advances towards its Phase 3 ReDiscover-2 trial in breast cancer. Dr. Mazumdar's extensive background, including her leadership at Bicara, prior roles at Rheos Medicines involving a partnership with Roche, and company formation experience at Third Rock Ventures, is particularly relevant given Relay's focus on developing precision medicines using its Dynamo® platform. The per-ticker sentiment for RLAY is moderately positive (0.3) following this governance update. Concurrently, Bicara Therapeutics has received favorable analyst coverage from Stifel and Cantor Fitzgerald, contributing to a strongly positive sentiment (0.7) for BCAX. Stifel maintained a Buy rating and a $48.00 price target on Bicara, expressing confidence in the ficerafusp and pembrolizumab combination for squamous cell carcinoma of the head and neck (SCCHN). Cantor Fitzgerald reaffirmed an Overweight rating, underscoring ficerafusp's potential to achieve significant tumor shrinkage in over 80% of responders, a figure noted as potentially superior to data from Merus NV, though direct comparisons are complex. Bicara's promising data includes an improved complete response rate of 21% and a 12-month overall survival rate of 61% for HPV-negative patients. However, both analyst firms prudently advise caution in drawing definitive conclusions from these results due to the small, non-randomized nature of the patient cohorts and highlighted the competitive oncology landscape discussed at the ASCO meeting, suggesting investors monitor future data releases. The overall news carries a 'strongly positive' sentiment score of 0.65 and a moderate market impact score of 0.55.

Key Decisions for Investors

• For Relay Therapeutics (RLAY), the appointment of Dr. Mazumdar strengthens its board's oncology expertise ahead of the crucial Phase 3 ReDiscover-2 trial; investors should monitor the trial's progress and subsequent data releases as key catalysts.
• Investors in Bicara Therapeutics (BCAX) should acknowledge the encouraging analyst ratings and promising early clinical data for ficerafusp, but remain vigilant regarding the limitations of small, non-randomized trial data and the competitive pressures within oncology, pending further clinical validation.
• Given the clinical-stage focus of both entities, portfolio allocations should reflect the inherent risk-reward profile of the biotech sector, with particular attention to upcoming clinical trial milestones and comparative efficacy data as they emerge.